Press Release: “the submission by the MAPS Public Benefit Corporation of the first-ever FDA New Drug Application (NDA) for MDMA-assisted therapy for PTSD!”

We are thrilled to share a momentous achievement in our journey towards revolutionizing mental health and drug policy – the submission by the MAPS Public Benefit Corporation of the first-ever FDA New Drug Application (NDA) for MDMA-assisted therapy for PTSD!

This milestone is a testament to the unwavering dedication and belief in our mission by thousands of donors like you. I am reaching out to express our deepest gratitude to you.

If all goes well, it’s possible that FDA approval for the prescription use of MDMA-assisted therapy for PTSD could take place around August 2024, with DEA rescheduling legally required to take place within 90 days after FDA approval.

To honor this milestone and ensure that our momentum continues, we are launching a special celebration campaign. We invite you to donate to MAPS to celebrate the NDA submission. This symbolic and practical gesture will mark this historic moment and contribute to sustaining our efforts in the next phase of research, education, and policy reform.

For over 37 ½ years, the generosity and commitment of MAPS supporters like yourself have played a pivotal role in advancing our research and paving the way for this groundbreaking moment. Your belief in the transformative power of psychedelic-assisted therapy has been a driving force, and today, we stand on the precipice of a new era in mental health care.

Your continued support is crucial as we navigate the challenges ahead and work towards making psychedelic healing — of all kinds — a reality for individuals seeking transformative experiences, whether in medical, religious, or a range of post-prohibition contexts. Please consider contributing and being part of the next steps of this exciting journey.

Thank you once again for your enduring support. Together, we are shaping a future where mental health is approached with innovation, compassion, and inclusivity.

With heartfelt gratitude,
Rick Doblin

 

P.S. The Phase 3 clinical trials and NDA submission were funded in part through multiple fundraising campaigns spearheaded by a challenge grant from Tim Ferriss and the Saisei Foundation and including grants from the Steven & Alexandra Cohen Foundation. Thousands of additional generous supporters, detailed here, joined us in this visionary quest.

Primary Sponsor


Get Connected

Karma Koala Podcast

Top Marijuana Blog